LL-37
LL-37 is a naturally occurring human antimicrobial peptide involved in innate immune defence. Its biological roles include interactions with microbes, immune cells and tissue responses following injury.
Its natural presence in the body has made therapeutic formulations a growing research focus. Any consideration of use at MRC begins with physician consultation and supervision.
What Is LL-37?
LL-37 is a 37-amino-acid peptide produced by processing the human cathelicidin precursor hCAP18. It is found in several tissues and immune-cell populations.
It participates in infection defence but also has complex inflammatory effects. Its activity depends on concentration, tissue environment and disease context.
How Does LL-37 Work?
LL-37 can interact with microbial membranes and influence immune-cell recruitment and signalling. Experimental studies also examine effects on epithelial repair and blood-vessel formation.
LL-37 has context-dependent immune actions, which is why physician assessment guides its use.
What Has Research Studied?
Studies include laboratory antimicrobial experiments and clinical trials of topical LL-37 for difficult-to-heal venous leg ulcers. Such trials evaluate specific preparations alongside structured wound care.
Findings from topical wound studies inform ongoing research into wider applications, always alongside standard wound management.
Safety and Medical Supervision
Clinical use is matched to the right formulation and route, with physician oversight of product quality and monitoring throughout.
Infected wounds, spreading redness, fever or worsening pain need prompt assessment. A physician should guide established care and determine whether a regulated clinical trial is appropriate.
Frequently Asked Questions
Is LL-37 an alternative to antibiotics?
Laboratory antimicrobial activity is a focus of ongoing research, and prescribed antibiotics and proper infection care remain essential.
Has LL-37 been studied in people?
Yes. Topical formulations have been examined in venous leg ulcer trials, but findings are specific to the studied preparation and clinical setting.
Does LL-37 always reduce inflammation?
It can regulate or promote inflammatory responses depending on the biological setting, which is why physician guidance matters.
Are injectable LL-37 products established medicines?
A physician assesses the evidence, product status and the options best suited to you.
References
- PubMed. LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity
- PubMed. Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Disclaimer
This information, including but not limited to texts, images, graphics, labels, ingredients, indications, potential benefits, and other materials contained on this website are for informational purposes only. No part of this website is intended to be a substitute for professional medical advice, treatment, or diagnosis. Always seek the advice of your physician or other professional healthcare provider, particularly before starting a new regimen for the first time.
Related Peptides
Wondering Whether LL-37 Is Right for You?
Speak with our medical team about your health goals. We will help you understand which options are supported by evidence and appropriate for your situation.